ACT Brief: FDA Clearance and Reimbursement for Wearables, Data Validation Across Complex Trials, and Wegovy HD Approval

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part four of his video interview, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, discussed how FDA clearance and reimbursement models influence wearable adoption in healthcare. FDA rigorous evaluation builds trust between device vendors and clinical providers, while reimbursement models must account for the time providers spend reviewing high-volume data streams to support broader integration into routine care.
• In a new contributed article, Jenna Phillips from PA Consulting examined how rigorous testing and validation prevent costly data issues discovered late in trials. As trials integrate data from multiple EHRs, wearables, and labs, small integration errors can trigger regulatory queries and delays. Organizations should establish end-to-end data validation as a scalable capability, using synthetic datasets and simulation before live patient enrollment to identify vulnerabilities across all system interfaces.
• The FDA approved Wegovy HD, a 7.2 mg once-weekly injectable semaglutide, based on Phase III trials showing mean weight loss of 20.7% in adults with obesity and 14.1% in those with type 2 diabetes. The approval, accelerated under the Commissioner's Priority Voucher Program, expands Novo Nordisk's semaglutide portfolio alongside the existing injectable and recently launched oral formulation, offering patients additional options for greater weight reduction.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.